Literature DB >> 9616052

Is the malaria diagnosis expensive?

P Penin1, E Vázquez, R Martínez, J A de Diego.   

Abstract

Malaria remains the most important of the tropical diseases, widespread throughout the tropics, but also occurring in many temperate regions. The disease causes a heavy toll of illness and death, among children in endemic areas. It also poses a risk to business travellers, tourists and immigrants and imported cases of malaria are increasingly seen in non-endemic areas. We discuss here how microscopical diagnosis is essential for identifying Plasmodium species responsible of the infection and discarding possible mixed infections. Thus, a correct treatment can be administered in 30 min, avoiding secondary stays and saving important amounts of money. Problems of drug resistance have to be distinguished from those arising due to erroneous diagnosis.

Entities:  

Mesh:

Year:  1998        PMID: 9616052     DOI: 10.1007/bf02815556

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  15 in total

1.  Chloroquine-resistant Plasmodium vivax: it may be a common problem.

Authors:  P J Collignon
Journal:  Med J Aust       Date:  1992-09-21       Impact factor: 7.738

2.  Chloroquine-Resistant Plasmodium vivax Malaria in Borneo.

Authors: 
Journal:  J Travel Med       Date:  1996-06-01       Impact factor: 8.490

3.  Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.

Authors:  B L Smoak; R F DeFraites; A J Magill; K C Kain; B T Wellde
Journal:  Am J Trop Med Hyg       Date:  1997-02       Impact factor: 2.345

4.  Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.

Authors:  L Signorini; A Matteelli; F Castelnuovo; F Castelli; O Oladeji; G Carosi
Journal:  Am J Trop Med Hyg       Date:  1996-11       Impact factor: 2.345

5.  High dose of primaquine in primaquine resistant vivax malaria.

Authors:  D Bunnag; J Karbwang; A Thanavibul; S Chittamas; Y Ratanapongse; K Chalermrut; K N Bangchang; T Harinasuta
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 Mar-Apr       Impact factor: 2.184

6.  Vivax malaria resistant to treatment and prophylaxis with chloroquine.

Authors:  G S Murphy; H Basri; E M Andersen; M J Bangs; D L Mount; J Gorden; A A Lal; A R Purwokusumo; S Harjosuwarno
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

7.  Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine.

Authors:  J K Baird; H Basri; B Subianto; D J Fryauff; P D McElroy; B Leksana; T L Richie; S Masbar; F S Wignall; S L Hoffman
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

8.  [A case of vivax malaria in which remission was achieved by primaquine at 1.5 times the standard dose after two earlier relapses].

Authors:  M Obana; S Ohta; Y Matsuoka; S Irimajiri; S Kano; M Suzuki
Journal:  Kansenshogaku Zasshi       Date:  1993-04

9.  The anaemia of P. falciparum malaria.

Authors:  S Abdalla; D J Weatherall; S N Wickramasinghe; M Hughes
Journal:  Br J Haematol       Date:  1980-10       Impact factor: 6.998

10.  Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.

Authors:  T Jelinek; H D Nothdurft; F Von Sonnenburg; T Loscher
Journal:  Am J Trop Med Hyg       Date:  1995-04       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.